NewAmsterdam Pharma Co N.V.
Close on Oct 19, 2026
- Market cap
- $2.53B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $3.70M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $3.00M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 18, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $300.00K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $19.10M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $3.00M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | $29.10M | $-0.18 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | $2.30M | $-0.41 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Press releases
Announcements NewAmsterdam Pharma filed with the SEC
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
Other events · EX-99.1 to Form 8-K
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Investor Presentation as of March 2, 2026 Nasdaq: NAMS
Regulation FD disclosure · EX-99.1 to Form 8-K
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation November 5, 2025 Nasdaq: NAMS
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Presentation September 2, 2025 Nasdaq: NAMS
Regulation FD disclosure · EX-99.1 to Form 8-K
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Obicetrapib in Alzheimer’s Disease (AD): First-in-Class Evidence from BROADWAY July 30, 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Welcome to R&D Day June 11, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
NewAmsterdam Pharma Announces Positive Topline Alzheimers Disease Data from BROADWAY Clinical Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimer This presentation (together with oral statements made in
Regulation FD disclosure · EX-99.2 to Form 8-K
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with
Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimer This presentation (together with oral statements made in
Regulation FD disclosure · EX-99.2 to Form 8-K
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disclaimer This presentation (together with oral statements made in
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BROOKLYN Topline Results July 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K